{"id":"sirolimus-sir","safety":{"commonSideEffects":[{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Mouth ulcers / stomatitis"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"5908cd1a-fc5a-462f-99ed-1d8983e253c9","title":"SIROLIMUS TABLET, SUGAR COATED [MYLAN PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus binds to FKBP12 and forms a complex that inhibits mTOR kinase activity, suppressing cell cycle progression and reducing protein synthesis. This mechanism makes it useful as an immunosuppressant and anti-cancer agent by blocking proliferation of T cells and tumor cells. It is particularly effective in preventing organ rejection and has activity in certain cancers driven by mTOR pathway activation.","oneSentence":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:27:19.867Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients"},{"name":"Various cancers with mTOR pathway activation (investigational)"}]},"trialDetails":[{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT06056193","phase":"NA","title":"The SIR-POBA Bypass Trial","status":"WITHDRAWN","sponsor":"Paracelsus Medical University","startDate":"2023-09-20","conditions":"Peripheral Arterial Occlusive Disease, Bypass Complication, Femoropopliteal Artery Occlusion","enrollment":""},{"nctId":"NCT06056206","phase":"NA","title":"The SIR-POBA Shunt Trial","status":"WITHDRAWN","sponsor":"Paracelsus Medical University","startDate":"2023-09-20","conditions":"Arteriovenous Fistula Stenosis","enrollment":""},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT05663944","phase":"PHASE2","title":"REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-07-25","conditions":"Advanced Chronic Liver Disease","enrollment":41},{"nctId":"NCT04374903","phase":"NA","title":"Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients","status":"WITHDRAWN","sponsor":"King Hussein Cancer Center","startDate":"2022-04-01","conditions":"COVID-19 Patients","enrollment":""},{"nctId":"NCT03018223","phase":"PHASE1","title":"Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-01-31","conditions":"Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia","enrollment":32},{"nctId":"NCT02588339","phase":"PHASE2","title":"Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-04","conditions":"Graft Versus Host Disease, GVHD","enrollment":42},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT01469572","phase":"PHASE1","title":"Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-12","conditions":"Neuroendocrine Tumors","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":121,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapamune"],"phase":"marketed","status":"active","brandName":"Sirolimus (SIR)","genericName":"Sirolimus (SIR)","companyName":"H. Lee Moffitt Cancer Center and Research Institute","companyId":"h-lee-moffitt-cancer-center-and-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation. Used for Prevention of organ rejection in transplant recipients, Various cancers with mTOR pathway activation (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}